title: Treatment with a new fusion inhibitor: patient issues with enfuvirtide (T-20). A review of the presentation at the satellite symposium "New hope: advancing care in HIV infection" at the 15th annual Association of Nurses in AIDS Care conference, November 2002.
abstract: The parenteral route of enfuvirtide administration requires that patients become familiar with reconstituting and administering the agent and in managing injection site reactions (ISRs). Since the majority of patients will experience at least one ISR, minimizing this effect is important, and several techniques can be taught to help alleviate the onset and symptoms of ISRs. Enfuvirtide patients usually encounter little difficulty with administration, and most report little impact of self-injections on their daily lives. However, instruction by nurses is crucial in training patients to administer enfuvirtide and to build this routine into their daily lives, thereby furthering the acceptance of enfuvirtide and promoting compliance. Patient education tools will provide clear and informative support, together with practical solutions to incorporate enfuvirtide therapy into daily life and travel. Easy access to the nurse and physician, coupled with an effective nurse-patient relationship, will be key in supporting good compliance with enfuvirtide therapy.
authors.affiliation: Quest Clinical Research, University of California, San Francisco, USA.
authors.forename: Eileen
authors.initials: E
authors.lastname: Glutzer
mesh_terms: D000077560:Enfuvirtide; D015700:HIV Envelope Protein gp41 / Q000008:administration & dosage / Q000627:therapeutic use*; D023581:HIV Fusion Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D007267:Injections; D009723:Nurse-Patient Relations; D010349:Patient Compliance; D010353:Patient Education as Topic; D010446:Peptide Fragments / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D015700:HIV Envelope Protein gp41; D023581:HIV Fusion Inhibitors; D010446:Peptide Fragments; D000077560:Enfuvirtide